Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203677 | 0.90 | PTGS2 (0.48) | PTGS2GRIA2CASP3SENP8SENP7 | |
| SCHEMBL5202343 | 0.85 | PTGS2 (0.52) | PTGS2GRIA2CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5207043 | 0.82 | PTGS2 (0.38) | PTGS2GRIA2CYP1A2CYP2D6 | |
| SCHEMBL5204760 | 0.79 | PTGS2 (0.41) | PTGS2 | |
| SCHEMBL5201734 | 0.78 | PTGS2 (0.66) | PTGS2CYP2D6CYP2C9 | |
| SCHEMBL5205075 | 0.78 | PTGS2 (0.46) | PTGS2 | |
| SCHEMBL5865711 | 0.78 | PTGS2 (0.46) | PTGS2CYP2D6CYP2C9 | |
| SCHEMBL5202342 | 0.77 | PTGS2 (0.46) | PTGS2 | |
| SCHEMBL5207141 | 0.76 | PTGS2 (0.40) | PTGS2CYP2C9 | |
| SCHEMBL5203972 | 0.76 | PTGS2 (0.47) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539718-A4 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORP (KR) | 2007-08-01 | — | — | EP | disclosed |
| US-7019144-B2 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CORP. (KR) | 2006-03-28 | — | — | US | disclosed |
| EP-1539718-A1 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ Corporation (KR) | 2005-06-15 | — | — | EP | disclosed |
| US-20050075507-A1 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CHEILJEDANG CORPORATION (KR) | 2005-04-07 | — | — | US | disclosed |
| WO-2004014878-A1 | 1,2,4-TRIAZOLE DERIVATIVE, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CJ CORPORATION (KR) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075507-A1 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CYP4B1, CYP3A5, CYP7A1 | PTGS2 1769/4885GRIA2 2265/4885CYP1A2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.